World Federation of Societies of Biological Psychiatry (WFSBP) guidelines update 2023 on the pharmacological treatment of eating disorders

References

• Agras WS, Dorian B, Kirkley BG, Arnow B, Bachman J. 1987. Imipramine in the treatment of bulimia: a double-blind controlled study. Int J Eat Disord. 6(1):29–38.
   Web of Science ®Google Scholar
• Agras WS, Rossiter EM, Arnow B, Schneider JA, Telch CF, Raeburn SD, Bruce B, Perl M, Koran LM. 1992. Pharmacologic and cognitive-behavioral treatment for bulimia nervosa: a controlled comparison. Am J Psychiatry. 149(1):82–87.
   PubMed Web of Science ®Google Scholar
• Agras WS, Rossiter EM, Arnow B, Telch CF, Raeburn SD, Bruce B, Koran LM. 1994. One-year follow-up of psychosocial and pharmacologic treatments for bulimia nervosa. J Clin Psychiatry. 55(5):179–183.
   PubMed Web of Science ®Google Scholar
• Ahmed MH. 2010. Orlistat and calcium oxalate crystalluria: an association that needs consideration. Ren Fail. 32(8):1019–1021.
   PubMed Web of Science ®Google Scholar
• Ahn J, Lee JH, Jung YC. 2019. Predictors of suicide attempts in individuals with eating disorders. Suicide Life Threat Behav. 49(3):789–797.
   PubMed Web of Science ®Google Scholar
• Aigner M, Treasure J, Kaye W, Kasper S. 2011. World federation of societies of biological psychiatry (WFSBP) guidelines for the pharmacological treatment of eating disorders. World J Biol Psychiatry. 12(6):400–443.
   PubMed Web of Science ®Google Scholar
• Alger SA, Schwalberg MD, Bigaouette JM, Michalek AV, Howard LJ. 1991. Effect of a tricyclic antidepressant and opiate antagonist on binge-eating behavior in normoweight bulimic and obese, binge-eating subjects. Am J Clin Nutr. 53(4):865–871.
   PubMed Web of Science ®Google Scholar
• Altamura AC, Moro AR, Percudani M. 1994. Clinical pharmacokinetics of fluoxetine. Clin Pharmacokinet. 26(3):201–214.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. 2012. Guideline watch: practice guideline for the treatment of patients with eating disorders. 3. American Psychiatric Association; [accessed].
   Google Scholar
• American Psychiatric Association. 2013. Diagnostic and statistical manual of mental disorders. 5th ed. Washington (DC): APA Publishing.
   Google Scholar
• American Psychiatric Association. 2022. Diagnostic and statistical manual of mental disorders. 5th (text rev.) ed. Washington (DC): APA Publishing.
   Google Scholar
• Andries A, Frystyk J, Flyvbjerg A, Støving RK. 2014. Dronabinol in severe, enduring anorexia nervosa: a randomized controlled trial. Int J Eat Disord. 47(1):18–23.
   PubMed Web of Science ®Google Scholar
• Andries A, Gram B, Støving RK. 2015. Effect of dronabinol therapy on physical activity in anorexia nervosa: a randomised, controlled trial. Eat Weight Disord. 20(1):13–21.
   PubMed Web of Science ®Google Scholar
• Antel J, Tan S, Grabler M, Ludwig C, Lohkemper D, Brandenburg T, Barth N, Hinney A, Libuda L, Remy M, et al. 2022. Rapid amelioration of anorexia nervosa in a male adolescent during metreleptin treatment including recovery from hypogonadotropic hypogonadism. Eur Child Adolesc Psychiatry. 31(10):1573–1579.
   PubMed Web of Science ®Google Scholar
• Appolinario JC, Bacaltchuk J, Sichieri R, Claudino AM, Godoy-Matos A, Morgan C, Zanella MT, Coutinho W. 2003. A randomized, double-blind, placebo-controlled study of sibutramine in the treatment of binge-eating disorder. Arch Gen Psychiatry. 60(11):1109–1116.
   PubMed Web of Science ®Google Scholar
• Appolinario JC, Fontenelle LF, Papelbaum M, Bueno JR, Coutinho W. 2002. Topiramate use in obese patients with binge eating disorder: an open study. Can J Psychiatry. 47(3):271–273.
   PubMed Web of Science ®Google Scholar
• Arnold LM, McElroy SL, Hudson JI, Welge JA, Bennett AJ, Keck PE. 2002. A placebo-controlled, randomized trial of fluoxetine in the treatment of binge-eating disorder. J Clin Psychiatry. 63(11):1028–1033.
   PubMed Web of Science ®Google Scholar
• Attia E, Haiman C, Walsh BT, Flater SR. 1998. Does fluoxetine augment the inpatient treatment of anorexia nervosa? AJP. 155(4):548–551.
   Google Scholar
• Attia E, Kaplan AS, Walsh BT, Gershkovich M, Yilmaz Z, Musante D, Wang Y. 2011. Olanzapine versus placebo for out-patients with anorexia nervosa. Psychol Med. 41(10):2177–2182.
   PubMed Web of Science ®Google Scholar
• Attia E, Steinglass JE, Walsh BT, Wang Y, Wu P, Schreyer C, Wildes J, Yilmaz Z, Guarda AS, Kaplan AS, et al. 2019. Olanzapine versus placebo in adult outpatients with anorexia nervosa: a randomized clinical trial. Am J Psychiatry. 176(6):449–456.
   PubMed Web of Science ®Google Scholar
• Ayyıldız H, Turan Ş, Gülcü D, Poyraz CA, Pehlivanoğlu E, Çullu F, Arıkan MK. 2016. Olanzapine-induced atypical neuroleptic malignant syndrome in an adolescent man with anorexia nervosa. Eat Weight Disord. 21(2):309–311.
   PubMed Web of Science ®Google Scholar
• Azad MAK, Sarker M, Wan D. 2018. Immunomodulatory effects of probiotics on cytokine profiles. Biomed Res Int. 2018:8063647.
   PubMed Web of Science ®Google Scholar
• Bacaltchuk J, Hay P. 2003. Antidepressants versus placebo for people with bulimia nervosa. Cochrane Database Syst Rev. 2003(4):CD003391.
   Google Scholar
• Barlow J, Blouin J, Blouin A, Perez E. 1988. Treatment of bulimia with desipramine: a double-blind crossover study. Can J Psychiatry. 33(2):129–133.
   PubMed Web of Science ®Google Scholar
• Bauer C, Fischer A, Keller U. 2006. Effect of sibutramine and of cognitive-behavioural weight loss therapy in obesity and subclinical binge eating disorder. Diabetes Obes Metab. 8(3):289–295.
   PubMed Web of Science ®Google Scholar
• Bertilsson L, Dahl ML, Dalén P, Al-Shurbaji A. 2002. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol. 53(2):111–122.
   PubMed Web of Science ®Google Scholar
• Bhatia MS, Gupta R. 2009. Pica responding to SSRI: an OCD spectrum disorder? World J Biol Psychiatry. 10(4 Pt 3):936–938.
   PubMed Web of Science ®Google Scholar
• Biederman J, Herzog DB, Rivinus TM, Harper GP, Ferber RA, Rozenbaum JF, Harmatz JS, Tondorf R, Orsulak PJ, Js J. 1985. Amitriptyline in the treatment of anorexia nervosa: a double-blind, placebo-controlled study. J Clin Psychopharmacol. 5(1):10–16.
   PubMed Web of Science ®Google Scholar
• Birmingham CL, Goldner EM, Bakan R. 1994. Controlled trial of zinc supplementation in anorexia nervosa. Intl J Eating Disorders. 15(3):251–255.
   PubMed Web of Science ®Google Scholar
• Bissada H, Tasca GA, Barber AM, Bradwejn J. 2008. Olanzapine in the treatment of low body weight and obsessive thinking in women with anorexia nervosa: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 165(10):1281–1288.
   PubMed Web of Science ®Google Scholar
• Black N, Varaganum M, Hutchings A. 2014. Relationship between patient reported experience (PREMs) and patient reported outcomes (PROMs) in elective surgery. BMJ Qual Saf. 23(7):534–542.
   PubMed Web of Science ®Google Scholar
• Blanchet C, Guillaume S, Bat-Pitault F, Carles M-E, Clarke J, Dodin V, Duriez P, Gerardin P, Hanachi-Guidoum M, Iceta S, et al. 2019. Medication in an: a multidisciplinary overview of Meta-Analyses and systematic reviews. JCM. 8(2):278.
   Google Scholar
• Blouin AG, Blouin JH, Perez EL, Bushnik T, Zuro C, Mulder E. 1988. Treatment of bulimia with fenfluramine and desipramine. J Clin Psychopharmacol. 8(4):261–269.
   PubMed Web of Science ®Google Scholar
• Brambilla F, Draisci A, Peirone A, Brunetta M. 1995. Combined cognitive-behavioral, psychopharmacological and nutritional therapy in bulimia nervosa. Neuropsychobiology. 32(2):68–71.
   PubMed Web of Science ®Google Scholar
• Brambilla F, Monteleone P, Maj M. 2007. Olanzapine-induced weight gain in anorexia nervosa: involvement of leptin and ghrelin secretion? Psychoneuroendocrinology. 32(4):402–406.
   PubMed Web of Science ®Google Scholar
• Brewerton TD, D'Agostino M. 2017. Adjunctive use of olanzapine in the treatment of avoidant restrictive food intake disorder in children and adolescents in an eating disorders program. J Child Adolesc Psychopharmacol. 27(10):920–922.
   PubMed Web of Science ®Google Scholar
• Broft AI, Spanos A, Corwin RL, Mayer L, Steinglass J, Devlin MJ, Attia E, Walsh BT. 2007. Baclofen for binge eating: an open-label trial. Int J Eat Disord. 40(8):687–691.
   PubMed Web of Science ®Google Scholar
• Bulik CM, Coleman JRI, Hardaway JA, Breithaupt L, Watson HJ, Bryant CD, Breen G. 2022. Genetics and neurobiology of eating disorders. Nat Neurosci. 25(5):543–554.
   PubMed Web of Science ®Google Scholar
• Carruba MO, Cuzzolaro M, Riva L, Bosello O, Liberti S, Castra R, D, Grave R, Santonastaso P, Garosi V, Nisoli E. 2001. Efficacy and tolerability of moclobemide in bulimia nervosa: a placebo-controlled trial. Int Clin Psychopharmacol. 16(1):27–32.
   PubMed Web of Science ®Google Scholar
• Casper RC, Schlemmer RF Jr., Javaid JI. 1987. A placebo-controlled crossover study of oral clonidine in acute anorexia nervosa. Psychiatry Res. 20(3):249–260.
   PubMed Web of Science ®Google Scholar
• Cassano GB, Miniati M, Pini S, Rotondo A, Banti S, Borri C, Camilleri V, Mauri M. 2003. Six month open trial of haloperidol as an adjunctive treatment for anorexia nervosa a preliminary report. Int J Eat Disord. 33(2):172–177.
   PubMed Web of Science ®Google Scholar
• Catone G, Pisano S, Muzzo G, Corrado G, Russo K, Maiorano A, Salerno F, Gritti A. 2020. A glance into psychiatric comorbidity in adolescents with anorexia nervosa. Minerva Pediatr. 72(6):501–507.
   PubMed Web of Science ®Google Scholar
• Chanoine JP, Hampl S, Jensen C, Boldrin M, Hauptman J. 2005. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA. 293(23):2873–2883.
   PubMed Web of Science ®Google Scholar
• Choure J, Quinn K, Franco K. 2006. Baking-soda pica in an adolescent patient. Psychosomatics. 47(6):531–532.
   PubMed Web of Science ®Google Scholar
• Christensen RC, Averbuch RN. 2009. The use of duloxetine in chronic bulimia nervosa: a case report. Psychiatry. 6(8):27–28.
   PubMedGoogle Scholar
• Claudino AM, de Oliveira IR, Appolinario JC, Cordás TA, Duchesne M, Sichieri R, Bacaltchuk J. 2007. Double-blind, randomized, placebo-controlled trial of topiramate plus cognitive-behavior therapy in binge-eating disorder. J Clin Psychiatry. 68(9):1324–1332.
   PubMed Web of Science ®Google Scholar
• Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, Schaff HV. 1997. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 337(9):581–588.
   PubMed Web of Science ®Google Scholar
• Cordás TA, Tavares H, Calderoni DM, Stump GV, Ribeiro RB. 2006. Oxcarbazepine for self-mutilating bulimic patients. Int J Neuropsychopharmacol. 9(6):769–771.
   PubMed Web of Science ®Google Scholar
• Corwin RL, Boan J, Peters KF, Ulbrecht JS. 2012. Baclofen reduces binge eating in a double-blind, placebo-controlled, crossover study. Behav Pharmacol. 23(5–6):616–625.
   PubMed Web of Science ®Google Scholar
• Crisp AH, Lacey JH, Crutchfield M. 1987. Clomipramine and ‘drive’ in people with anorexia nervosa: an in-patient study. Br J Psychiatry. 150(3):355–358.
   PubMedGoogle Scholar
• Dagan Y, Yager J. 2018. Severe bupropion XR abuse in a patient with long-standing bulimia nervosa and complex PTSD. Int J Eat Disord. 51(10):1207–1209.
   PubMed Web of Science ®Google Scholar
• de Beaurepaire R, Joussaume B, Rapp A, Jaury P. 2015. Treatment of binge eating disorder with high-dose baclofen: a case series. J Clin Psychopharmacol. 35(3):357–359.
   PubMed Web of Science ®Google Scholar
• de Vos J, Houtzager L, Katsaragaki G, van de Berg E, Cuijpers P, Dekker J. 2014. Meta analysis on the efficacy of pharmacotherapy versus placebo on anorexia nervosa. J Eat Disord. 2(1):27.
   PubMedGoogle Scholar
• de Zwaan M, Nutzinger DO, Schoenbeck G. 1992. Binge eating in overweight women. Compr Psychiatry. 33(4):256–261.
   PubMed Web of Science ®Google Scholar
• Dechant E, Boyle B, A Ross R. 2020. Ketamine in a patient with comorbid anorexia and MDD. J Women’s Health Dev. 3(3):373–375.
   Google Scholar
• Devlin MJ, Goldfein JA, Petkova E, Jiang H, Raizman PS, Wolk S, Mayer L, Carino J, Bellace D, Kamenetz C, et al. 2005. Cognitive behavioral therapy and fluoxetine as adjuncts to group behavioral therapy for binge eating disorder. Obes Res. 13(6):1077–1088.
   PubMedGoogle Scholar
• Devlin MJ, Goldfein JA, Petkova E, Liu L, Walsh BT. 2007. Cognitive behavioral therapy and fluoxetine for binge eating disorder: two-year follow-up. Obesity. 15(7):1702–1709.
   PubMed Web of Science ®Google Scholar
• Dhopatkar N, Keeler JL, Mutwalli H, Whelan K, Treasure J, Himmerich H. 2023. Gastrointestinal symptoms, gut microbiome, probiotics and prebiotics in anorexia nervosa: a review of mechanistic rationale and clinical evidence. Psychoneuroendocrinology. 147:105959.
   PubMed Web of Science ®Google Scholar
• Dold M, Aigner M, Klabunde M, Treasure J, Kasper S. 2015. Second-generation antipsychotic drugs in anorexia nervosa: a meta-analysis of randomized controlled trials. Psychother Psychosom. 84(2):110–116.
   PubMed Web of Science ®Google Scholar
• Dolman L, Thornley S, Doxtdator K, Leclerc A, Findlay S, Grant C, Breakey VR, Couturier J. 2021. Multimodal therapy for rigid, persistent avoidant/restrictive food intake disorder (ARFID) since infancy: a case report. Clin Child Psychol Psychiatry. 26(2):451–463.
   PubMed Web of Science ®Google Scholar
• El-Giamal N, de Zwaan M, Bailer U, Lennkh C, Schüssler P, Strnad A, Kasper S. 2000. Reboxetine in the treatment of bulimia nervosa: a report of seven cases. Int Clin Psychopharmacol. 15(6):351–356.
   PubMed Web of Science ®Google Scholar
• Fahy TA, Eisler I, Russell GF. 1993. A placebo-controlled trial of d-fenfluramine in bulimia nervosa. Br J Psychiatry. 162(5):597–603.
   PubMedGoogle Scholar
• Faris PL, Kim SW, Meller WH, Goodale RL, Oakman SA, Hofbauer RD, Marshall AM, Daughters RS, Banerjee-Stevens D, Eckert ED, et al. 2000. Effect of decreasing afferent vagal activity with ondansetron on symptoms of bulimia nervosa: a randomised, double-blind trial. Lancet. 355(9206):792–797.
   PubMed Web of Science ®Google Scholar
• Fassino S, Daga GA, Boggio S, Garzaro L, Pierò A. 2004. Use of reboxetine in bulimia nervosa: a pilot study. J Psychopharmacol. 18(3):423–428.
   PubMed Web of Science ®Google Scholar
• Fassino S, Leombruni P, Daga GA, Brustolin A, Migliaretti G, Cavallo F, Rovera GG. 2002. Efficacy of citalopram in anorexia nervosa: a pilot study. Eur Neuropsychopharmacol. 12(5):453–459.
   PubMed Web of Science ®Google Scholar
• Fassino S, Pierò A, Tomba E, Abbate-Daga G. 2009. Factors associated with dropout from treatment for eating disorders: a comprehensive literature review. BMC Psychiatry. 9(1):67.
   PubMed Web of Science ®Google Scholar
• Fazeli PK, Lawson EA, Faje AT, Eddy KT, Lee H, Fiedorek FT, Breggia A, Gaal IM, DeSanti R, Klibanski A. 2018. Treatment with a ghrelin agonist in outpatient women with anorrexia nervosa: a randomized clinical trial. J Clin Psychiatry. 79(1):17m11585.
   PubMed Web of Science ®Google Scholar
• Fazeli PK, Lawson EA, Prabhakaran R, Miller KK, Donoho DA, Clemmons DR, Herzog DB, Misra M, Klibanski A. 2010. Effects of recombinant human growth hormone in anorexia nervosa: a randomized, placebo-controlled study. J Clin Endocrinol Metab. 95(11):4889–4897.
   PubMed Web of Science ®Google Scholar
• Fekih-Romdhane F, Cheour M. 2022. A rare case report of teen-onset pica in a female patient with a clinical high risk for psychosis. Early Interv Psychiatry. 16(7):808–811.
   PubMed Web of Science ®Google Scholar
• Ferguson CP, La Via MC, Crossan PJ, Kaye WH. 1999. Are serotonin selective reuptake inhibitors effective in underweight anorexia nervosa? Int J Eat Disord. 25(1):11–17.
   PubMed Web of Science ®Google Scholar
• Ferreira GM, Nazar BP, da Silva MR, Carriello MA, Freitas S, Appolinario JC. 2018. Misuse of sibutramine and bulimia nervosa: a dangerous combination. Braz J Psychiatry. 40(3):343.
   PubMedGoogle Scholar
• Fichter MM, Krüger R, Rief W, Holland R, Döhne J. 1996. Fluvoxamine in prevention of relapse in bulimia nervosa: effects on eating-specific psychopathology. J Clin Psychopharmacol. 16(1):9–18.
   PubMed Web of Science ®Google Scholar
• Fichter MM, Leibl K, Rief W, Brunner E, Schmidt-Auberger S, Engel RR. 1991. Fluoxetine versus placebo: a double-blind study with bulimic inpatients undergoing intensive psychotherapy. Pharmacopsychiatry. 24(1):1–7.
   PubMed Web of Science ®Google Scholar
• Fluoxetine Bulimia Nervosa Collaborative Study Group. 1992. Fluoxetine in the treatment of bulimia nervosa. A multicenter, placebo-controlled, double-blind trial. Fluoxetine bulimia nervosa collaborative study group. Arch Gen Psychiatry. 49(2):139–147.
   PubMed Web of Science ®Google Scholar
• Foster JA, McVey Neufeld KA. 2013. Gut-brain axis: how the microbiome influences anxiety and depression. Trends Neurosci. 36(5):305–312.
   PubMed Web of Science ®Google Scholar
• Frank GKW. 2016. Aripiprazole, a partial dopamine agonist to improve adolescent anorexia nervosa a case series. Int J Eat Disord. 49(5):529–533.
   PubMed Web of Science ®Google Scholar
• Frank GKW, Shott ME, Hagman JO, Schiel MA, DeGuzman MC, Rossi B. 2017. The partial dopamine D2 receptor agonist aripiprazole is associated with weight gain in adolescent anorexia nervosa. Int J Eat Disord. 50(4):447–450.
   PubMed Web of Science ®Google Scholar
• Galmiche M, Déchelotte P, Lambert G, Tavolacci MP. 2019. Prevalence of eating disorders over the 2000–2018 period: a systematic literature review. Am J Clin Nutr. 109(5):1402–1413.
   PubMed Web of Science ®Google Scholar
• Golay A, Laurent-Jaccard A, Habicht F, Gachoud JP, Chabloz M, Kammer A, Schutz Y. 2005. Effect of orlistat in obese patients with binge eating disorder. Obes Res. 13(10):1701–1708.
   PubMedGoogle Scholar
• Goldberg SC, Halmi KA, Eckert ED, Casper RC, Davis JM. 1979. Cyproheptadine in anorexia nervosa. Br J Psychiatry. 134(1):67–70.
   PubMedGoogle Scholar
• Goldbloom DS, Olmsted M, Davis R, Clewes J, Heinmaa M, Rockert W, Shaw B. 1997. A randomized controlled trial of fluoxetine and cognitive behavioral therapy for bulimia nervosa: short-term outcome. Behav Res Ther. 35(9):803–811.
   PubMed Web of Science ®Google Scholar
• Goldstein DJ, Wilson MG, Thompson VL, Potvin JH, Rampey AH Jr. 1995. Long-term fluoxetine treatment of bulimia nervosa. Fluoxetine bulimia nervosa research group. Br J Psychiatry. 166(5):660–666.
   PubMedGoogle Scholar
• Gradl-Dietsch G, Milos G, Wabitsch M, Bell R, Tschöpe F, Antel J, Hebebrand J. 2023. Rapid emergence of appetite and hunger resulting in weight gain and improvement of eating disorder symptomatology during and after short-term off-label metreleptin treatment of a patient with anorexia nervosa. Obes Facts. 16(1):99–107.
   PubMed Web of Science ®Google Scholar
• Graham DJ, Green L. 1997. Further cases of valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 337(9):635.
   PubMed Web of Science ®Google Scholar
• Grant JE, Valle S, Cavic E, Redden SA, Chamberlain SR. 2019. A double-blind, placebo-controlled study of vortioxetine in the treatment of binge-eating disorder. Int J Eat Disord. 52(7):786–794.
   PubMed Web of Science ®Google Scholar
• Gray E, Chen T, Menzel J, Schwartz T, Kaye WH. 2018. Mirtazapine and weight gain in avoidant and restrictive food intake disorder. J Am Acad Child Adolesc Psychiatry. 57(4):288–289.
   PubMed Web of Science ®Google Scholar
• Green M, Arora K, Prakash S. 2020. Microbial medicine: prebiotic and probiotic functional foods to target obesity and metabolic syndrome. Int J Mol Sci. 21(8):2890.
   PubMed Web of Science ®Google Scholar
• Grilo CM, Crosby RD, Wilson GT, Masheb RM. 2012. 12-Month follow-up of fluoxetine and cognitive behavioral therapy for binge eating disorder. J Consult Clin Psychol. 80(6):1108–1113.
   PubMed Web of Science ®Google Scholar
• Grilo CM, Lydecker JA, Morgan PT, Gueorguieva R. 2021. Naltrexone + bupropion combination for the treatment of binge-eating disorder with obesity: a randomized, controlled pilot study. Clin Ther. 43(1):112–122.e111.
   PubMed Web of Science ®Google Scholar
• Grilo CM, Masheb RM, Crosby RD. 2012. Predictors and moderators of response to cognitive behavioral therapy and medication for the treatment of binge eating disorder. J Consult Clin Psychol. 80(5):897–906.
   PubMed Web of Science ®Google Scholar
• Grilo CM, Masheb RM, Salant SL. 2005. Cognitive behavioral therapy guided self-help and orlistat for the treatment of binge eating disorder: a randomized, double-blind, placebo-controlled trial. Biol Psychiatry. 57(10):1193–1201.
   PubMed Web of Science ®Google Scholar
• Grilo CM, Masheb RM, White MA, Gueorguieva R, Barnes RD, Walsh BT, McKenzie KC, Genao I, Garcia R. 2014. Treatment of binge eating disorder in racially and ethnically diverse obese patients in primary care: randomized placebo-controlled clinical trial of self-help and medication. Behav Res Ther. 58:1–9.
   PubMed Web of Science ®Google Scholar
• Grilo CM, Masheb RM, Wilson GT. 2005. Efficacy of cognitive behavioral therapy and fluoxetine for the treatment of binge eating disorder: a randomized double-blind placebo-controlled comparison. Biol Psychiatry. 57(3):301–309.
   PubMed Web of Science ®Google Scholar
• Grilo CM, Masheb RM, Wilson GT. 2006. Rapid response to treatment for binge eating disorder. J Consult Clin Psychol. 74(3):602–613.
   PubMed Web of Science ®Google Scholar
• Grilo CM, McElroy SL, Hudson JI, Tsai J, Navia B, Goldman R, Deng L, Kent J, Loebel A. 2021. Efficacy and safety of dasotraline in adults with binge-eating disorder: a randomized, placebo-controlled, fixed-dose clinical trial. CNS Spectr. 26(5):481–490.
   PubMed Web of Science ®Google Scholar
• Grilo CM, White MA. 2013. Orlistat with behavioral weight loss for obesity with versus without binge eating disorder: randomized placebo-controlled trial at a community mental health center serving educationally and economically disadvantaged Latino/as. Behav Res Ther. 51(3):167–175.
   PubMed Web of Science ®Google Scholar
• Grilo CM, White MA, Masheb RM, Gueorguieva R. 2015. Predicting meaningful outcomes to medication and self-help treatments for binge-eating disorder in primary care: the significance of early rapid response. J Consult Clin Psychol. 83(2):387–394.
   PubMed Web of Science ®Google Scholar
• Gross HA, Ebert MH, Faden VB, Goldberg SC, Kaye WH, Caine ED, Hawks R, Zinberg N. 1983. A double-blind trial of delta 9-tetrahydrocannabinol in primary anorexia nervosa. J Clin Psychopharmacol. 3(3):165–171.
   PubMed Web of Science ®Google Scholar
• Gross HA, Ebert MH, Faden VB, Goldberg SC, Nee LE, Kaye WH. 1981. A double-blind controlled trial of lithium carbonate primary anorexia nervosa. J Clin Psychopharmacol. 1(6):376–381.
   PubMed Web of Science ®Google Scholar
• Guerdjikova AI, Blom TJ, Martens BE, Keck PE Jr., McElroy SL. 2013. Zonisamide in the treatment of bulimia nervosa: an open-label, pilot, prospective study. Int J Eat Disord. 46(7):747–750.
   PubMed Web of Science ®Google Scholar
• Guerdjikova AI, Blom TJ, Mori N, McElroy SL. 2013. N-acetylcysteine in bulimia nervosa–open-label trial. Eat Behav. 14(1):87–89.
   PubMed Web of Science ®Google Scholar
• Guerdjikova AI, Kotwal R, McElroy SL. 2005. Response of recurrent binge eating and weight gain to topiramate in patients with binge eating disorder after bariatric surgery. Obes Surg. 15(2):273–277.
   PubMed Web of Science ®Google Scholar
• Guerdjikova AI, McElroy SL. 2013. Adjunctive methylphenidate in the treatment of bulimia nervosa co-occurring with bipolar disorder and substance dependence. Innov Clin Neurosci. 10(2):30–33.
   PubMedGoogle Scholar
• Guerdjikova AI, McElroy SL, Kotwal R, Welge JA, Nelson E, Lake K, Alessio DD, Keck PE Jr., Hudson JI. 2008. High-dose escitalopram in the treatment of binge-eating disorder with obesity: a placebo-controlled monotherapy trial. Hum Psychopharmacol. 23(1):1–11.
   PubMed Web of Science ®Google Scholar
• Guerdjikova AI, McElroy SL, Welge JA, Nelson E, Keck PE, Hudson JI. 2009. Lamotrigine in the treatment of binge-eating disorder with obesity: a randomized, placebo-controlled monotherapy trial. Int Clin Psychopharmacol. 24(3):150–158.
   PubMed Web of Science ®Google Scholar
• Guerdjikova AI, Mori N, Blom TJ, Keck PE Jr., Williams SL, Welge JA, McElroy SL. 2016. Lisdexamfetamine dimesylate in binge eating disorder: a placebo controlled trial. Hum Psychopharmacol. 31(5):382–391.
   PubMed Web of Science ®Google Scholar
• Guerdjikova AI, Williams S, Blom TJ, Mori N, McElroy SL. 2018. Combination phentermine-topiramate extended release for the treatment of binge eating disorder: an open-label, prospective study. Innov Clin Neurosci. 15(5–6):17–21.
   PubMedGoogle Scholar
• Hagman J, Gralla J, Sigel E, Ellert S, Dodge M, Gardner R, O'Lonergan T, Frank G, Wamboldt MZ. 2011. A double-blind, placebo-controlled study of risperidone for the treatment of adolescents and young adults with anorexia nervosa: a pilot study. J Am Acad Child Adolesc Psychiatry. 50(9):915–924.
   PubMed Web of Science ®Google Scholar
• Halmi KA, Eckert E, Ladu TJ, Cohen J. 1986. Anorexia nervosa: treatment efficacy of cyproheptadine and amitriptyline. Arch Gen Psychiatry. 43(2):177–181.
   PubMed Web of Science ®Google Scholar
• Hart M, Sibbritt D, Williams LT, Nunn KP, Wilcken B. 2021. Progressing our understanding of the impacts of nutrition on the brain and behaviour in anorexia nervosa: a tyrosine case study example. J Eat Disord. 9(1):86.
   PubMed Web of Science ®Google Scholar
• Haruta I, Asakawa A, Inui A. 2014. Olanzapine-induced hypoglycemia in anorexia nervosa. Endocrine. 46(3):672–673.
   PubMed Web of Science ®Google Scholar
• Haruta I, Fuku Y, Kinoshita K, Yoneda K, Morinaga A, Amitani M, Amitani H, Asakawa A, Sugawara H, Takeda Y, et al. 2015. One-year intranasal application of growth hormone releasing peptide-2 improves body weight and hypoglycemia in a severely emaciated anorexia nervosa patient. J Cachexia Sarcopenia Muscle. 6(3):237–241.
   PubMed Web of Science ®Google Scholar
• Hasan A, Bandelow B, Yatham LN, Berk M, Falkai P, Möller HJ, Kasper S. 2019. WFSBP guidelines on how to grade treatment evidence for clinical guideline development. World J Biol Psychiatry. 20(1):2–16.
   PubMed Web of Science ®Google Scholar
• Hay P, Chinn D, Forbes D, Madden S, Newton R, Sugenor L, Touyz S, Ward W. 2014. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of eating disorders. Aust N Z J Psychiatry. 48(11):977–1008.
   PubMed Web of Science ®Google Scholar
• Hazen E, Fava M. 2006. Successful treatment with duloxetine in a case of treatment refractory bulimia nervosa: a case report. J Psychopharmacol. 20(5):723–724.
   PubMed Web of Science ®Google Scholar
• Hebebrand J, Milos G, Wabitsch M, Teufel M, Führer D, Bühlmeier J, Libuda L, Ludwig C, Antel J. 2019. Clinical trials required to assess potential benefits and side effects of treatment of patients with anorexia nervosa with recombinant human leptin. Front Psychol. 10:769.
   PubMed Web of Science ®Google Scholar
• Hedges DW, Reimherr FW, Hoopes SP, Rosenthal NR, Kamin M, Karim R, Capece JA. 2003. Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, part 2: improvement in psychiatric measures. J Clin Psychiatry. 64(12):1449–1454.
   PubMed Web of Science ®Google Scholar
• Hergüner A, Hergüner S. 2016. Pica in an adolescent with autism spectrum disorder responsive to aripiprazole. J Child Adolesc Psychopharmacol. 26(1):80–81.
   PubMed Web of Science ®Google Scholar
• Hergüner S, Hergüner AS. 2010. Pica in a child with attention deficit hyperactivity disorder and successful treatment with methylphenidate. Prog Neuropsychopharmacol Biol Psychiatry. 34(6):1155–1156.
   PubMed Web of Science ®Google Scholar
• Herpertz S, Fichter M, Herpertz-Dahlmann B, Hilbert A, Tuschen-Caffier B, Vocks S, Zeeck A. 2018. S3-Leitlinie diagnostik und behandlung der essstörungen. 2nd ed. Berlin; Heidelberg: Springer.
   Google Scholar
• Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, Eckermann G, Egberts K, Gerlach M, Greiner C, et al. 2018. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 51(1–2):9–62.
   PubMed Web of Science ®Google Scholar
• Hilbert A, Petroff D, Herpertz S, Pietrowsky R, Tuschen-Caffier B, Vocks S, Schmidt R. 2019. Meta-analysis of the efficacy of psychological and medical treatments for binge-eating disorder. J Consult Clin Psychol. 87(1):91–105.
   PubMed Web of Science ®Google Scholar
• Hilbert A, Petroff D, Herpertz S, Pietrowsky R, Tuschen-Caffier B, Vocks S, Schmidt R. 2020. Meta-analysis on the long-term effectiveness of psychological and medical treatments for binge-eating disorder. Int J Eat Disord. 53(9):1353–1376.
   PubMed Web of Science ®Google Scholar
• Hill K, Bucuvalas J, McClain C, Kryscio R, Martini RT, Alfaro MP, Maloney M. 2000. Pilot study of growth hormone administration during the refeeding of malnourished anorexia nervosa patients. J Child Adolesc Psychopharmacol. 10(1):3–8.
   PubMed Web of Science ®Google Scholar
• Himmerich H, Kan C, Au K, Treasure J. 2021. Pharmacological treatment of eating disorders, comorbid mental health problems, malnutrition and physical health consequences. Pharmacol Ther. 217:107667.
   PubMed Web of Science ®Google Scholar
• Himmerich H, Treasure J. 2018. Psychopharmacological advances in eating disorders. Expert Rev Clin Pharmacol. 11(1):95–108.
   PubMed Web of Science ®Google Scholar
• Hoopes SP, Reimherr FW, Hedges DW, Rosenthal NR, Kamin M, Karim R, Capece JA, Karvois D. 2003. Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, part 1: improvement in binge and purge measures. J Clin Psychiatry. 64(11):1335–1341.
   PubMed Web of Science ®Google Scholar
• Horne RL, Ferguson JM, Pope HG Jr., Hudson JI, Lineberry CG, Ascher J, Cato A. 1988. Treatment of bulimia with bupropion: a multicenter controlled trial. J Clin Psychiatry. 49(7):262–266.
   PubMed Web of Science ®Google Scholar
• Hsu LK, Clement L, Santhouse R, Ju ES. 1991. Treatment of bulimia nervosa with lithium carbonate. A controlled study. J Nerv Ment Dis. 179(6):351–355.
   PubMed Web of Science ®Google Scholar
• Hudson JI, McElroy SL, Ferreira-Cornwell MC, Radewonuk J, Gasior M. 2017. Efficacy of lisdexamfetamine in adults with moderate to severe binge-eating disorder: a randomized clinical trial. JAMA Psychiatry. 74(9):903–910.
   PubMed Web of Science ®Google Scholar
• Hudson JI, McElroy SL, Raymond NC, Crow S, Keck PE Jr., Carter WP, Mitchell JE, Strakowski SM, Pope HG Jr., Coleman BS, et al. 1998. Fluvoxamine in the treatment of binge-eating disorder: a multicenter placebo-controlled, double-blind trial. Am J Psychiatry. 155(12):1756–1762.
   PubMed Web of Science ®Google Scholar
• Hughes PL, Wells LA, Cunningham CJ, Ilstrup DM. 1986. Treating bulimia with desipramine. A double-blind, placebo-controlled study. Arch Gen Psychiatry. 43(2):182–186.
   PubMed Web of Science ®Google Scholar
• Huseman C, Pearson P, Madison J, Leuschen M. 1990. Bulimia as a form of self-addiction-treatment with naltrexone hydrochloride (trexan)—a pilot-study. Clin Trials J. 27(2):77–83.
   Google Scholar
• Ikeda M, Shigenobu K, Fukuhara R, Hokoishi K, Maki N, Nebu A, Komori K, Tanabe H. 2004. Efficacy of fluvoxamine as a treatment for behavioral symptoms in frontotemporal lobar degeneration patients. Dement Geriatr Cogn Disord. 17(3):117–121.
   PubMed Web of Science ®Google Scholar
• Jacobi C, Dahme B, Dittmann R. 2002. Cognitive-behavioural, fluoxetine and combined treatment for bulimia nervosa: short- and long-term results. Eur Eat Disorders Rev. 10(3):179–198.
   Web of Science ®Google Scholar
• Jonas JM, Gold MS. 1988. The use of opiate antagonists in treating bulimia: a study of low-dose versus high-dose naltrexone. Psychiatry Res. 24(2):195–199.
   PubMed Web of Science ®Google Scholar
• Kafantaris V, Leigh E, Hertz S, Berest A, Schebendach J, Sterling WM, Saito E, Sunday S, Higdon C, Golden NH, et al. 2011. A placebo-controlled pilot study of adjunctive olanzapine for adolescents with anorexia nervosa. J Child Adolesc Psychopharmacol. 21(3):207–212.
   PubMed Web of Science ®Google Scholar
• Kalaria SN, McElroy SL, Gobburu J, Gopalakrishnan M. 2020. An innovative disease-drug-trial framework to guide binge eating disorder drug development: a case study for topiramate. Clin Transl Sci. 13(1):88–97.
   PubMed Web of Science ®Google Scholar
• Kan C, Eid L, Treasure J, Himmerich H. 2020. A meta-analysis of dropout and metabolic effects of antipsychotics in anorexia nervosa. Front Psychiatry. 11:208.
   PubMed Web of Science ®Google Scholar
• Kanamori T, Kaneko Y, Yamada K, Suzuki M. 2021. Successful combination therapy of trazodone and fluvoxamine for pica in Alzheimer’s disease: a case report. Front Psychiatry. 12:704847.
   PubMed Web of Science ®Google Scholar
• Kaplan AS, Garfinkel PE, Darby PL, Garner DM. 1983. Carbamazepine in the treatment of bulimia. Am J Psychiatry. 140(9):1225–1226.
   PubMed Web of Science ®Google Scholar
• Katsambas AD, Dessinioti C. 2010. Hormonal therapy for acne: why not as first line therapy? Facts and controversies. Clin Dermatol. 28(1):17–23.
   PubMed Web of Science ®Google Scholar
• Katz RL, Keen CL, Litt IF, Hurley LS, Kellams-Harrison KM, Glader LJ. 1987. Zinc deficiency in anorexi nervosa. J Adolesc Health Care. 8(5):400–406.
   PubMedGoogle Scholar
• Katzman DK, Norris ML, Zucker N. 2019. Avoidant restrictive food intake disorder. Psychiatr Clin North Am. 42(1):45–57.
   PubMed Web of Science ®Google Scholar
• Kaye WH, Nagata T, Weltzin TE, Hsu LKG, Sokol MS, McConaha C, Plotnicov KH, Weise J, Deep D. 2001. Double-blind placebo-controlled administration of fluoxetine in restricting- and restricting-purging-type anorexia nervosa. Biol Psychiatry. 49(7):644–652.
   PubMed Web of Science ®Google Scholar
• Keeler JL, Treasure J, Juruena MF, Kan C, Himmerich H. 2021. Ketamine as a treatment for anorexia nervosa: a narrative review. Nutrients. 13(11):4158.
   PubMed Web of Science ®Google Scholar
• Kennedy SH, Goldbloom DS, Ralevski E, Davis C, D'Souza JD, Lofchy J. 1993. Is there a role for selective monoamine oxidase inhibitor therapy in bulimia nervosa? A placebo-controlled trial of brofaromine. J Clin Psychopharmacol. 13(6):415–422.
   PubMed Web of Science ®Google Scholar
• Kennedy SH, Piran N, Warsh JJ, Prendergast P, Mainprize E, Whynot C, Garfinkel PE. 1988. A trial of isocarboxazid in the treatment of bulimia nervosa. J Clin Psychopharmacol. 8(6):391–396.
   PubMed Web of Science ®Google Scholar
• Keshen AR, Dixon L, Ali SI, Helson T, Nunes A, Milliken H, Gamberg S, Sadek J, Kaplan A, McElroy SL. 2021. A feasibility study evaluating lisdexamfetamine dimesylate for the treatment of adults with bulimia nervosa. Int J Eat Disord. 54(5):872–878.
   PubMed Web of Science ®Google Scholar
• Kim YR, Eom JS, Leppanen J, Leslie M, Treasure J. 2018. Effects of intranasal oxytocin on the attentional bias to emotional stimuli in patients with bulimia nervosa. Psychoneuroendocrinology. 91:75–78.
   PubMed Web of Science ®Google Scholar
• Kim YR, Eom JS, Yang JW, Kang J, Treasure J. 2015. The impact of oxytocin on food intake and emotion recognition in patients with eating disorders: a double blind single dose within-subject cross-over design. PLOS One. 10(9):e0137514.
   PubMed Web of Science ®Google Scholar
• Kimball A, Schorr M, Meenaghan E, Bachmann KN, Eddy KT, Misra M, Lawson EA, Kreiger-Benson E, Herzog DB, Koman S, et al. 2019. A randomized placebo-controlled trial of low-dose testosterone therapy in women with anorexia nervosa. J Clin Endocrinol Metab. 104(10):4347–4355.
   PubMed Web of Science ®Google Scholar
• Kishi T, Kafantaris V, Sunday S, Sheridan EM, Correll CU. 2012. Are antipsychotics effective for the treatment of anorexia nervosa? Results from a systematic review and meta-analysis. J Clin Psychiatry. 73(6):757–766.
   PubMedGoogle Scholar
• Kotler LA, Devlin MJ, Davies M, Walsh BT. 2003. An open trial of fluoxetine for adolescents with bulimia nervosa. J Child Adolesc Psychopharmacol. 13(3):329–335.
   PubMed Web of Science ®Google Scholar
• Laederach-Hofmann K, Graf C, Horber F, Lippuner K, Lederer S, Michel R, Schneider M. 1999. Imipramine and diet counseling with psychological support in the treatment of obese binge eaters: a randomized, placebo-controlled double-blind study. Int J Eat Disord. 26(3):231–244.
   PubMed Web of Science ®Google Scholar
• Lebert F, Stekke W, Hasenbroekx C, Pasquier F. 2004. Frontotemporal dementia: a randomised, controlled trial with trazodone. Dement Geriatr Cogn Disord. 17(4):355–359.
   PubMed Web of Science ®Google Scholar
• Lebow J, Sim LA, Erwin PJ, Murad MH. 2013. The effect of atypical antipsychotic medications in individuals with anorexia nervosa: a systematic review and meta-analysis. Int J Eat Disord. 46(4):332–339.
   PubMed Web of Science ®Google Scholar
• Lee H, Rhee PL, Park EH, Kim JH, Son HJ, Kim JJ, Rhee JC. 2007. Clinical outcome of rumination syndrome in adults without psychiatric illness: a prospective study. J Gastroenterol Hepatol. 22(11):1741–1747.
   PubMed Web of Science ®Google Scholar
• Léger J, Fjellestad-Paulsen A, Bargiacchi A, Pages J, Chevenne D, Alison M, Alberti C, Guilmin-Crepon S. 2021. One year of GH treatment for growth failure in children with anorexia nervosa: a randomized placebo-controlled trial. J Clin Endocrinol Metab. 106(7):e2535–e2546.
   PubMed Web of Science ®Google Scholar
• Leggero C, Masi G, Brunori E, Calderoni S, Carissimo R, Maestro S, Muratori F. 2010. Low-dose olanzapine monotherapy in girls with anorexia nervosa, restricting subtype: focus on hyperactivity. J Child Adolesc Psychopharmacol. 20(2):127–133.
   PubMed Web of Science ®Google Scholar
• Leombruni P, Amianto F, Delsedime N, Gramaglia C, Abbate-Daga G, Fassino S. 2006. Citalopram versus fluoxetine for the treatment of patients with bulimia nervosa: a single-blind randomized controlled trial. Adv Ther. 23(3):481–494.
   PubMed Web of Science ®Google Scholar
• Leombruni P, Pierò A, Brustolin A, Mondelli V, Levi M, Campisi S, Marozio S, Abbate-Daga G, Fassino S. 2006. A 12 to 24 weeks pilot study of sertraline treatment in obese women binge eaters. Hum Psychopharmacol. 21(3):181–188.
   PubMed Web of Science ®Google Scholar
• Leombruni P, Pierò A, Lavagnino L, Brustolin A, Campisi S, Fassino S. 2008. A randomized, double-blind trial comparing sertraline and fluoxetine 6-month treatment in obese patients with binge eating disorder. Prog Neuropsychopharmacol Biol Psychiatry. 32(6):1599–1605.
   PubMed Web of Science ®Google Scholar
• Leslie M, Leppanen J, Paloyelis Y, Nazar BP, Treasure J. 2019. The influence of oxytocin on risk-taking in the balloon analogue risk task among women with bulimia nervosa and binge eating disorder. J Neuroendocrinol. 31(8):e12771.
   PubMed Web of Science ®Google Scholar
• Levinson CA, Rodebaugh TL, Fewell L, Kass AE, Riley EN, Stark L, McCallum K, Lenze EJ. 2015. D-cycloserine facilitation of exposure therapy improves weight regain in patients with anorexia nervosa: a pilot randomized controlled trial. J Clin Psychiatry. 76(6):e787–e793.
   PubMed Web of Science ®Google Scholar
• Linardon J, Wade TD. 2018. How many individuals achieve symptom abstinence following psychological treatments for bulimia nervosa? A meta-analytic review. Int J Eat Disord. 51(4):287–294.
   PubMed Web of Science ®Google Scholar
• Luzier J, Rached K, Talley J. 2019. Relapse prevention and selective serotonin reuptake inhibitor medication in two adolescents with anorexia nervosa. Int J Eat Disord. 52(7):863–867.
   PubMed Web of Science ®Google Scholar
• Mahr F, Billman M, Essayli JH, Lane Loney SE. 2022. Selective serotonin reuptake inhibitors and hydroxyzine in the treatment of avoidant/restrictive food intake disorder in children and adolescents: rationale and evidence. J Child Adolesc Psychopharmacol. 32(2):117–121. eng.
   PubMed Web of Science ®Google Scholar
• Malhotra S, King KH, Welge JA, Brusman-Lovins L, McElroy SL. 2002. Venlafaxine treatment of binge-eating disorder associated with obesity: a series of 35 patients. J Clin Psychiatry. 63(9):802–806.
   PubMed Web of Science ®Google Scholar
• Manos BE, Bravender TD, Harrison TM, Lange HLH, Cottrill CB, Abdel-Rasoul M, Bonny AE. 2018. A pilot randomized controlled trial of omega-3 fatty acid supplementation for the treatment of anxiety in adolescents with anorexia nervosa. Int J Eat Disord. 51(12):1367–1372.
   PubMed Web of Science ®Google Scholar
• Marcus MD, Wing RR, Ewing L, Kern E, McDermott M, Gooding W. 1990. A double-blind, placebo-controlled trial of fluoxetine plus behavior modification in the treatment of obese binge-eaters and non-binge-eaters. Am J Psychiatry. 147(7):876–881.
   PubMed Web of Science ®Google Scholar
• Marrazzi MA, Bacon JP, Kinzie, J, Luby, ED. 1995. Naltrexone use in the treatment of anorexia nervosa and bulimia nervosa. Int Clin Psychopharmacol. 10:163–172.
   PubMed Web of Science ®Google Scholar
• Martínez Insfran LA, Alconchel Gago F, Parrilla Paricio P. 2019. Fulminant liver failure secondary to submassive hepatic necrosis in a patient treated with orlistat. A case report. Rev Esp Enferm Dig. 111(1):83.
   PubMed Web of Science ®Google Scholar
• Marzola E, Desedime N, Giovannone C, Amianto F, Fassino S, Abbate-Daga G. 2015. Atypical antipsychotics as augmentation therapy in anorexia nervosa. PLOS One. 10(4):e0125569.
   PubMed Web of Science ®Google Scholar
• Mauri M, Miniati M, Mariani MG, Ciberti A, Dell’Osso L. 2013. Haloperidol for severe anorexia nervosa restricting type with delusional body image disturbance: a nine-case chart review. Eat Weight Disord. 18(3):329–332.
   PubMed Web of Science ®Google Scholar
• McCallum RW, Grill BB, Lange R, Planky M, Glass EE, Greenfeld DG. 1985. Definition of a gastric emptying abnormality in patients with anorexia nervosa. Dig Dis Sci. 30(8):713–722.
   PubMed Web of Science ®Google Scholar
• McCann UD, Agras WS. 1990. Successful treatment of nonpurging bulimia nervosa with desipramine: a double-blind, placebo-controlled study. Am J Psychiatry. 147(11):1509–1513.
   PubMed Web of Science ®Google Scholar
• McDuffie JR, Calis KA, Uwaifo GI, Sebring NG, Fallon EM, Frazer TE, V, Hubbard S, Yanovski JA. 2004. Efficacy of orlistat as an adjunct to behavioral treatment in overweight African American and Caucasian adolescents with obesity-related co-morbid conditions. J Pediatr Endocrinol Metab. 17(3):307–319.
   PubMed Web of Science ®Google Scholar
• McDuffie JR, Calis KA, Uwaifo GI, Sebring NG, Fallon EM, Hubbard VS, Yanovski JA. 2002. Three-month tolerability of orlistat in adolescents with obesity-related comorbid conditions. Obes Res. 10(7):642–650.
   PubMedGoogle Scholar
• McElroy SL, Arnold LM, Shapira NA, Keck PE Jr., Rosenthal NR, Karim MR, Kamin M, Hudson JI. 2003. Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial. Am J Psychiatry. 160(2):255–261.
   PubMed Web of Science ®Google Scholar
• McElroy SL, Casuto LS, Nelson EB, Lake KA, Soutullo CA, Keck PE Jr., Hudson JI. 2000. Placebo-controlled trial of sertraline in the treatment of binge eating disorder. Am J Psychiatry. 157(6):1004–1006.
   PubMed Web of Science ®Google Scholar
• McElroy SL, Guerdjikova A, Kotwal R, Welge JA, Nelson EB, Lake KA, Keck PE Jr., Hudson JI. 2007. Atomoxetine in the treatment of binge-eating disorder: a randomized placebo-controlled trial. J Clin Psychiatry. 68(3):390–398.
   PubMed Web of Science ®Google Scholar
• McElroy SL, Guerdjikova AI, Mori N, Romo-Nava F. 2019. Progress in developing pharmacologic agents to treat bulimia nervosa. CNS Drugs. 33(1):31–46.
   PubMed Web of Science ®Google Scholar
• McElroy SL, Guerdjikova AI, Winstanley EL, O'Melia AM, Mori N, Keck PE Jr., Hudson JI. 2011. Sodium oxybate in the treatment of binge eating disorder: an open-label, prospective study. Int J Eat Disord. 44(3):262–268.
   PubMed Web of Science ®Google Scholar
• McElroy SL, Hudson JI, Capece JA, Beyers K, Fisher AC, Rosenthal NR. 2007. Topiramate for the treatment of binge eating disorder associated with obesity: a placebo-controlled study. Biol Psychiatry. 61(9):1039–1048.
   PubMed Web of Science ®Google Scholar
• McElroy SL, Hudson J, Ferreira-Cornwell MC, Radewonuk J, Whitaker T, Gasior M. 2016. Lisdexamfetamine dimesylate for adults with moderate to severe binge eating disorder: results of two pivotal phase 3 randomized controlled trials. Neuropsychopharmacology. 41(5):1251–1260.
   PubMed Web of Science ®Google Scholar
• McElroy SL, Hudson JI, Grilo CM, Guerdjikova AI, Deng L, Koblan KS, Goldman R, Navia B, Hopkins S, Loebel A. 2020. Efficacy and safety of dasotraline in adults with binge-eating disorder: a randomized, placebo-controlled, flexible-dose clinical trial. J Clin Psychiatry. 81(5):19m13068.
   PubMed Web of Science ®Google Scholar
• McElroy SL, Hudson JI, Malhotra S, Welge JA, Nelson EB, Keck PE Jr. 2003. Citalopram in the treatment of binge-eating disorder: a placebo-controlled trial. J Clin Psychiatry. 64(7):807–813.
   PubMed Web of Science ®Google Scholar
• McElroy SL, Hudson JI, Mitchell JE, Wilfley D, Ferreira-Cornwell MC, Gao J, Wang J, Whitaker T, Jonas J, Gasior M. 2015. Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge-eating disorder: a randomized clinical trial. JAMA Psychiatry. 72(3):235–246.
   PubMed Web of Science ®Google Scholar
• McElroy SL, Kotwal R, Guerdjikova AI, Welge JA, Nelson EB, Lake KA, D'Alessio DA, Keck PE, Hudson JI. 2006. Zonisamide in the treatment of binge eating disorder with obesity: a randomized controlled trial. J Clin Psychiatry. 67(12):1897–1906.
   PubMed Web of Science ®Google Scholar
• McElroy SL, Kotwal R, Hudson JI, Nelson EB, Keck PE. 2004. Zonisamide in the treatment of binge-eating disorder: an open-label, prospective trial. J Clin Psychiatry. 65(1):50–56.
   PubMed Web of Science ®Google Scholar
• McElroy SL, Shapira NA, Arnold LM, Keck PE, Rosenthal NR, Wu SC, Capece JA, Fazzio L, Hudson JI. 2004. Topiramate in the long-term treatment of binge-eating disorder associated with obesity. J Clin Psychiatry. 65(11):1463–1469.
   PubMed Web of Science ®Google Scholar
• Milano W, Petrella C, Casella A, Capasso A, Carrino S, Milano L. 2005. Use of sibutramine, an inhibitor of the reuptake of serotonin and noradrenaline, in the treatment of binge eating disorder: a placebo-controlled study. Adv Ther. 22(1):25–31.
   PubMed Web of Science ®Google Scholar
• Milano W, Petrella C, Sabatino C, Capasso A. 2004. Treatment of bulimia nervosa with sertraline: a randomized controlled trial. Adv Ther. 21(4):232–237.
   PubMed Web of Science ®Google Scholar
• Mills IH, Park GR, Manara AR, Merriman RJ. 1998. Treatment of compulsive behaviour in eating disorders with intermittent ketamine infusions. QJM. 91(7):493–503.
   PubMedGoogle Scholar
• Milos G, Antel J, Kaufmann LK, Barth N, Koller A, Tan S, Wiesing U, Hinney A, Libuda L, Wabitsch M, et al. 2020. Short-term metreleptin treatment of patients with anorexia nervosa: rapid on-set of beneficial cognitive, emotional, and behavioral effects. Transl Psychiatry. 10(1):303. eng.
   PubMed Web of Science ®Google Scholar
• Mitchell JE, Christenson G, Jennings J, Huber M, Thomas B, Pomeroy C, Morley J. 1989. A placebo-controlled, double-blind crossover study of naltrexone hydrochloride in outpatients with normal weight bulimia. J Clin Psychopharmacol. 9(2):94–97.
   PubMed Web of Science ®Google Scholar
• Mitchell JE, Fletcher L, Hanson K, Mussell MP, Seim H, Crosby R, Al-Banna M. 2001. The relative efficacy of fluoxetine and manual-based self-help in the treatment of outpatients with bulimia nervosa. J Clin Psychopharmacol. 21(3):298–304.
   PubMed Web of Science ®Google Scholar
• Mitchell JE, Groat R. 1984. A placebo-controlled, double-blind trial of amitriptyline in bulimia. J Clin Psychopharmacol. 4(4):186–193.
   PubMed Web of Science ®Google Scholar
• Mitchell JE, Pyle RL, Eckert ED, Hatsukami D, Pomeroy C, Zimmerman R. 1990. A comparison study of antidepressants and structured intensive group psychotherapy in the treatment of bulimia nervosa. Arch Gen Psychiatry. 47(2):149–157.
   PubMed Web of Science ®Google Scholar
• Monteleone AM, Pellegrino F, Croatto G, Carfagno M, Hilbert A, Treasure J, Wade T, Bulik CM, Zipfel S, Hay P, et al. 2022. Treatment of eating disorders: a systematic meta-review of meta-analyses and network meta-analyses. Neurosci Biobehav Rev. 142:104857.
   PubMed Web of Science ®Google Scholar
• Murphy LE, Fonseka TM, Bousman CA, Müller DJ. 2022. Gene-drug pairings for antidepressants and antipsychotics: level of evidence and clinical application. Mol Psychiatry. 27(1):593–605.
   PubMed Web of Science ®Google Scholar
• Naguy A, Al-Mutairi A. 2018. An adolescent male with anorexia nervosa favorably responded to mirtazapine. Am J Ther. 25(6):E675–E676.
   PubMed Web of Science ®Google Scholar
• Naguy A, Roshdy R, Al-Mutairi A, Alwetayan S, Alamiri B. 2021. Mirtazapine improved eating patterns in avoidant/restrictive food intake disorder. Am J Ther. [DOI: 10.1097/MJT.0000000000001338].
   Web of Science ®Google Scholar
• Naviaux AF. 2019. Management of ARFID (avoidant restrictive food intake disorder) in a 12-year-old on a paediatric ward in a general hospital: use of mirtazapine, partial hospitalisation model and family based therapy. Psychiatr Danub. 31(Suppl 3):421–426.
   PubMedGoogle Scholar
• NICE. 2017. Eating disorders: recognition and treatment. [accessed 2019 Dec 21]. https://www.nice.org.uk/guidance/ng69.
   Google Scholar
• Nickel C, Tritt K, Muehlbacher M, Pedrosa Gil F, Mitterlehner FO, Kaplan P, Lahmann C, Leiberich PK, Krawczyk J, Kettler C, et al. 2005. Topiramate treatment in bulimia nervosa patients: a randomized, double-blind, placebo-controlled trial. Int J Eat Disord. 38(4):295–300.
   PubMed Web of Science ®Google Scholar
• Norgren S, Danielsson P, Jurold R, Lötborn M, Marcus C. 2003. Orlistat treatment in obese prepubertal children: a pilot study. Acta Paediatr. 92(6):666–670.
   PubMed Web of Science ®Google Scholar
• Nova E, Toro O, Varela P, López-Vidriero I, Morandé G, Marcos A. 2006. Effects of a nutritional intervention with yogurt on lymphocyte subsets and cytokine production capacity in anorexia nervosa patients. Eur J Nutr. 45(4):225–233.
   PubMed Web of Science ®Google Scholar
• Okita K, Shiina A, Nakazato M, Iyo M. 2013. Tandospirone, a 5-HT1A partial agonist is effective in treating anorexia nervosa: a case series. Ann Gen Psychiatry. 12(1):7.
   PubMedGoogle Scholar
• Pauwels A, Broers C, Van Houtte B, Rommel N, Vanuytsel T, Tack J. 2018. A randomized double-blind, placebo-controlled, cross-over study using baclofen in the treatment of rumination syndrome. Am J Gastroenterol. 113(1):97–104.
   PubMed Web of Science ®Google Scholar
• Pearlstein T, Spurell E, Hohlstein LA, Gurney V, Read J, Fuchs C, Keller MB. 2003. A double-blind, placebo-controlled trial of fluvoxamine in binge eating disorder: a high placebo response. Arch Womens Ment Health. 6(2):147–151.
   PubMedGoogle Scholar
• Peña-Salazar C, Kazah N. 2020. Pica disorder as a symptom of depression in a patient with bipolar disorder and intellectual disability. Actas Esp Psiquiatr. 48(1):36–46.
   PubMed Web of Science ®Google Scholar
• Pope HG Jr., Hudson JI, Jonas JM, Yurgelun-Todd D. 1983. Bulimia treated with imipramine: a placebo-controlled, double-blind study. Am J Psychiatry. 140(5):554–558.
   PubMed Web of Science ®Google Scholar
• Pope HG Jr., Keck PE Jr., McElroy SL, Hudson JI. 1989. A placebo-controlled study of trazodone in bulimia nervosa. J Clin Psychopharmacol. 9(4):254–259.
   PubMed Web of Science ®Google Scholar
• Powers PS, Klabunde M, Kaye W. 2012. Double-blind placebo-controlled trial of quetiapine in anorexia nervosa. Eur Eat Disord Rev. 20(4):331–334.
   PubMed Web of Science ®Google Scholar
• Pruccoli J, Parmeggiani A. 2022. Inpatient treatment of anorexia nervosa with adjunctive valproate: a case series of 14 young and adolescent patients. Eat Weight Disord. 27[(3):1209–1215.
   PubMed Web of Science ®Google Scholar
• Pruccoli J, Pettenuzzo I, Parmeggiani A. 2022. Low-dose olanzapine in the treatment of adolescents with anorexia nervosa: an observational naturalistic case-control study. J Child Adolesc Psychopharmacol. 32(5):304–310.
   PubMed Web of Science ®Google Scholar
• Pugh JN, Sparks AS, Doran DA, Fleming SC, Langan-Evans C, Kirk B, Fearn R, Morton JP, Close GL. 2019. Four weeks of probiotic supplementation reduces GI symptoms during a marathon race. Eur J Appl Physiol. 119(7):1491–1501.
   PubMed Web of Science ®Google Scholar
• Quilty LC, Allen TA, Davis C, Knyahnytska Y, Kaplan AS. 2019. A randomized comparison of long acting methylphenidate and cognitive behavioral therapy in the treatment of binge eating disorder. Psychiatry Res. 273:467–474.
   PubMed Web of Science ®Google Scholar
• Ricca V, Castellini G, L, Sauro C, Rotella CM, Faravelli C. 2009. Zonisamide combined with cognitive behavioral therapy in binge eating disorder: a one-year follow-up study. Psychiatry. 6(11):23–28.
   PubMedGoogle Scholar
• Ricca V, Mannucci E, Mezzani B, Moretti S, Di Bernardo M, Bertelli M, Rotella CM, Faravelli C. 2001. Fluoxetine and fluvoxamine combined with individual cognitive-behaviour therapy in binge eating disorder: a one-year follow-up study. Psychother Psychosom. 70(6):298–306.
   PubMed Web of Science ®Google Scholar
• Ricoux O, Carton L, Ménard O, Deheul S, Gautier S, Bordet R, Cottencin O. 2019. Acute psychosis related to baclofen in a patient treated for binge eating disorder highlights the urgent need to regulate off-label prescriptions. J Clin Psychopharmacol. 39(3):282–284.
   PubMed Web of Science ®Google Scholar
• Robert SA, Rohana AG, Shah SA, Chinna K, Wan Mohamud WN, Kamaruddin NA. 2015. Improvement in binge eating in non-diabetic obese individuals after 3 months of treatment with liraglutide–a pilot study. Obes Res Clin Pract. 9(3):301–304.
   PubMed Web of Science ®Google Scholar
• Romano SJ, Halmi KA, Sarkar NP, Koke SC, Lee JS. 2002. A placebo-controlled study of fluoxetine in continued treatment of bulimia nervosa after successful acute fluoxetine treatment. AJP. 159(1):96–102.
   Google Scholar
• Rothschild R, Quitkin HM, Quitkin FM, Stewart JW, Ocepek-Welikson K, McGrath PJ, Tricamo E. 1994. A double-blind placebo-controlled comparison of phenelzine and imipramine in the treatment of bulimia in atypical depressives. Int J Eat Disord. 15(1):1–9.
   PubMed Web of Science ®Google Scholar
• Ruggiero GM, Laini V, Mauri MC, Ferrari VM, Clemente A, Lugo F, Mantero M, Redaelli G, Zappulli D, Cavagnini F. 2001. A single blind comparison of amisulpride, fluoxetine and clomipramine in the treatment of restricting anorectics. Prog Neuropsychopharmacol Biol Psychiatry. 25(5):1049–1059.
   PubMed Web of Science ®Google Scholar
• Russell DM, Freedman ML, Feiglin DH, Jeejeebhoy KN, Swinson RP, Garfinkel PE. 1983. Delayed gastric emptying and improvement with domperidone in a patient with anorexia nervosa. Am J Psychiatry. 140(9):1235–1236.
   PubMed Web of Science ®Google Scholar
• Russell J, Maguire S, Hunt GE, Kesby A, Suraev A, Stuart J, Booth J, McGregor IS. 2018. Intranasal oxytocin in the treatment of anorexia nervosa: randomized controlled trial during re-feeding. Psychoneuroendocrinology. 87:83–92.
   PubMed Web of Science ®Google Scholar
• Sabine EJ, Yonace A, Farrington AJ, Barratt KH, Wakeling A. 1983. Bulimia nervosa: a placebo controlled double-blind therapeutic trial of mianserin. Br J Clin Pharmacol. 15(Suppl 2): S195–S202.
   Google Scholar
• Safer DL, Adler S, Dalai SS, Bentley JP, Toyama H, Pajarito S, Najarian T. 2020. A randomized, placebo-controlled crossover trial of phentermine-topiramate ER in patients with binge-eating disorder and bulimia nervosa. Int J Eat Disord. 53(2):266–277.
   PubMed Web of Science ®Google Scholar
• Safer DL, Darcy AM, Lock J. 2011. Use of mirtazapine in an adult with refractory anorexia nervosa and comorbid depression: a case report. Int J Eat Disord. 44(2):178–181.
   PubMed Web of Science ®Google Scholar
• Saleh JW, Lebwohl P. 1980. Metoclopramide‐induced gastric emptying in patients with anorexia nervosa. Am J Gastroenterol. 74(2):127–132.
   PubMed Web of Science ®Google Scholar
• Sall D, Wang J, Rashkin M, Welch M, Droege C, Schauer D. 2014. Orlistat-induced fulminant hepatic failure. Clin Obes. 4(6):342–347.
   PubMedGoogle Scholar
• Santomauro DF, Melen S, Mitchison D, Vos T, Whiteford H, Ferrari AJ. 2021. The hidden burden of eating disorders: an extension of estimates from the global burden of disease study 2019. Lancet Psychiatry. 8(4):320–328.
   PubMed Web of Science ®Google Scholar
• Santonastaso P, Friederici S, Favaro A. 2001. Sertraline in the treatment of restricting anorexia nervosa: an open controlled trial. J Child Adolesc Psychopharmacol. 11(2):143–150.
   PubMed Web of Science ®Google Scholar
• Sayer M, Duche A, Nguyen TJT, Le M, Patel K, Vu J, Pham D, Vernick B, Beuttler R, Roosan D, et al. 2021. Clinical implications of combinatorial pharmacogenomic tests based on cytochrome P450 variant selection. Front Genet. 12:719671.
   PubMed Web of Science ®Google Scholar
• Schmidt U, Adan R, Böhm I, Campbell IC, Dingemans A, Ehrlich S, Elzakkers I, Favaro A, Giel K, Harrison A, et al. 2016. Eating disorders: the big issue. Lancet Psychiatry. 3(4):313–315.
   PubMed Web of Science ®Google Scholar
• Schmidt U, Cooper PJ, Essers H, Freeman CP, Holland RL, Palmer RL, Shur E, Russell GF, Bowler C, Coker S, et al. 2004. Fluvoxamine and graded psychotherapy in the treatment of bulimia nervosa: a randomized, double-blind, placebo-controlled, multicenter study of short-term and long-term pharmacotherapy combined with a stepped care approach to psychotherapy. J Clin Psychopharmacol. 24(5):549–552.
   PubMed Web of Science ®Google Scholar
• Schwartz T, Trunko ME, Feifel D, Lopez E, Peterson D, Frank GKW, Kaye W. 2021. A longitudinal case series of IM ketamine for patients with severe and enduring eating disorders and comorbid treatment-resistant depression. Clin Case Rep. 9(5):e03869.
   PubMed Web of Science ®Google Scholar
• Scolnick B, Zupec-Kania B, Calabrese L, Aoki C, Hildebrandt T. 2020. Remission from chronic anorexia nervosa with ketogenic diet and ketamine: case report. Front Psychiatry. 11:763.
   PubMed Web of Science ®Google Scholar
• Sharma H. 2021. Statistical significance or clinical significance? A researcher’s dilemma for appropriate interpretation of research results. Saudi J Anaesth. 15(4):431–434.
   PubMed Web of Science ®Google Scholar
• SIGN. 2019. A guideline developer’s handbook. SIGN publication no. 50. Edinburgh; [updated 2019 Nov; accessed]. http://www.sign.ac.uk.
   Google Scholar
• Silén Y, Sipilä PN, Raevuori A, Mustelin L, Marttunen M, Kaprio J, Keski-Rahkonen A. 2020. DSM-5 eating disorders among adolescents and young adults in Finland: a public health concern. Int J Eat Disord. 53(5):520–531.
   PubMed Web of Science ®Google Scholar
• Silveira RO, Zanatto V, Appolinário JC, Kapczinski F. 2005. An open trial of reboxetine in obese patients with binge eating disorder. Eat Weight Disord. 10(4):e93–e96.
   PubMedGoogle Scholar
• Sokol MS, Gray NS, Goldstein A, Kaye WH. 1999. Methylphenidate treatment for bulimia nervosa associated with a cluster B personality disorder. Int J Eat Disord. 25(2):233–237.
   PubMed Web of Science ®Google Scholar
• Solis B, Nova E, Gómez S, Samartín S, Mouane N, Lemtouni A, Belaoui H, Marcos A. 2002. The effect of fermented milk on interferon production in malnourished children and in anorexia nervosa patients undergoing nutritional care. Eur J Clin Nutr. 56 Suppl 4:S27–S33.
   PubMed Web of Science ®Google Scholar
• Solmi M, Santonastaso P, Caccaro R, Favaro A. 2013. A case of anorexia nervosa with comorbid Crohn’s disease: beneficial effects of anti-TNF-α therapy? Int J Eat Disord. 46(6):639–641.
   PubMed Web of Science ®Google Scholar
• Spettigue W, Buchholz A, Henderson K, Feder S, Moher D, Kourad K, Gaboury I, Norris M, Ledoux S. 2008. Evaluation of the efficacy and safety of olanzapine as an adjunctive treatment for anorexia nervosa in adolescent females: a randomized, double-blind, placebo-controlled trial. BMC Pediatr. 8(1):1–9.
   PubMedGoogle Scholar
• Spettigue W, Norris ML, Maras D, Obeid N, Feder S, Harrison ME, Gomez R, Fu MCY, Henderson K, Buchholz A. 2018. Evaluation of the effectiveness and safety of olanzapine as an adjunctive treatment for anorexia nervosa in adolescents: an open-label trial. J Can Acad Child Adolesc Psychiatry. 27(3):197–208.
   PubMed Web of Science ®Google Scholar
• Spettigue W, Norris ML, Santos A, Obeid N. 2018. Treatment of children and adolescents with avoidant/restrictive food intake disorder: a case series examining the feasibility of family therapy and adjunctive treatments. J Eat Disord. 6:20.
   PubMed Web of Science ®Google Scholar
• Spriggs MJ, Douglass HM, Park RJ, Read T, Danby JL, de Magalhães FJC, Alderton KL, Williams TM, Blemings A, Lafrance A, et al. 2021. Study protocol for “psilocybin” as a treatment for anorexia nervosa: a pilot study. Front Psychiatry. 12:735523.
   PubMed Web of Science ®Google Scholar
• Stacher G, Abatzi-Wenzel TA, Wiesnagrotzki S, Bergmann H, Schneider C, Gaupmann G. 1993. Gastric emptying, body weight and symptoms in primary anorexia nervosa. Long-term effects of cisapride. Br J Psychiatry. 162(3):398–402.
   PubMedGoogle Scholar
• Stacher G, Bergmann H, Wiesnagrotzki S, Kiss A, Schneider C, Mittelbach G, Gaupmann G, Höbart J. 1987. Intravenous cisapride accelerates delayed gastric emptying and increases antral contraction amplitude in patients with primary anorexia nervosa. Gastroenterol. 92(4):1000–1006.
   PubMed Web of Science ®Google Scholar
• Steinglass J, Kaplan SC, Liu Y, Wang Y, Walsh BT. 2014. The (lack of) effect of alprazolam on eating behavior in anorexia nervosa: a preliminary report. Int J Eat Disord. 47(8):901–904.
   PubMed Web of Science ®Google Scholar
• Steinglass J, Sysko R, Schebendach J, Broft A, Strober M, Walsh BT. 2007. The application of exposure therapy and D-cycloserine to the treatment of anorexia nervosa: a preliminary trial. J Psychiatr Pract. 13(4):238–245.
   PubMedGoogle Scholar
• Stunkard A, Berkowitz R, Tanrikut C, Reiss E, Young L. 1996. d-fenfluramine treatment of binge eating disorder. Am J Psychiatry. 153(11):1455–1459.
   PubMed Web of Science ®Google Scholar
• Sundblad C, Landén M, Eriksson T, Bergman L, Eriksson E. 2005. Effects of the androgen antagonist flutamide and the serotonin reuptake inhibitor citalopram in bulimia nervosa: a placebo-controlled pilot study. J Clin Psychopharmacol. 25(1):85–88.
   PubMed Web of Science ®Google Scholar
• Sysko R, Sha N, Wang Y, Duan N, Walsh BT. 2010. Early response to antidepressant treatment in bulimia nervosa. Psychol Med. 40(6):999–1005.
   PubMed Web of Science ®Google Scholar
• Szmukler GI, Young GP, Miller G, Lichtenstein M, Binns DS. 1995. A controlled trial of cisapride in anorexia nervosa. Int J Eat Disord. 17(4):347–357.
   PubMed Web of Science ®Google Scholar
• Tahıllıoğlu A, Özcan T, Yüksel G, Majroh N, Köse S, Özbaran B. 2020. Is aripiprazole a key to unlock anorexia nervosa?: a case series. Clin Case Rep. 8(12):2827–2834.
   PubMed Web of Science ®Google Scholar
• Tak YJ, Lee SY. 2021. Long-Term efficacy and safety of anti-obesity treatment: where do we stand? Curr Obes Rep. 10(1):14–30.
   PubMed Web of Science ®Google Scholar
• Treasure J, Hübel C, Himmerich H. 2022. The evolving epidemiology and differential etiopathogenesis of eating disorders: implications for prevention and treatment. World Psychiatry. 21(1):147–148.
   PubMed Web of Science ®Google Scholar
• Trunko ME, Schwartz TA, Berner LA, Cusack A, Nakamura T, Bailer UF, Chen JY, Kaye WH. 2017. A pilot open series of lamotrigine in DBT-treated eating disorders characterized by significant affective dysregulation and poor impulse control. Borderline Personal Disord Emot Dysregul. 4(1):1–10.
   PubMedGoogle Scholar
• Trunko ME, Schwartz TA, Duvvuri V, Kaye WH. 2011. Aripiprazole in anorexia nervosa and low-weight bulimia nervosa: case reports. Int J Eat Disord. 44(3):269–275.
   PubMed Web of Science ®Google Scholar
• Trunko ME, Schwartz TA, Marzola E, Klein AS, Kaye WH. 2014. Lamotrigine use in patients with binge eating and purging, significant affect dysregulation, and poor impulse control. Int J Eat Disord. 47(3):329–334.
   PubMed Web of Science ®Google Scholar
• Tyrrell-Bunge E, de Carvalho AF, Scott C, Tomlin S, Treasure J, Himmerich H. 2018. A three level-intervention to reduce PRN medication on a specialist eating disorders ward for adult female patients with anorexia nervosa. Psychiatr Danub. 30(1):107–108.
   PubMed Web of Science ®Google Scholar
• Ulfvebrand S, Birgegård A, Norring C, Högdahl L, von Hausswolff-Juhlin Y. 2015. Psychiatric comorbidity in women and men with eating disorders results from a large clinical database. Psychiatry Res. 230(2):294–299.
   PubMed Web of Science ®Google Scholar
• Umehara H, Iga J, Ohmori T. 2014. Successful treatment of anorexia nervosa in a 10-year-old boy with risperidone long-acting injection. Clin Psychopharmacol Neurosci. 12(1):65–66.
   PubMed Web of Science ®Google Scholar
• Upadhyaya SK, Sharma A. 2012. Onset of obsessive compulsive disorder in pregnancy with pica as the sole manifestation. Indian J Psychol Med. 34(3):276–278.
   PubMedGoogle Scholar
• US Food and Drug Administration. 2008. Statistical review and evaluation: antiepileptic drugs and suicidality. Silver Spring (MD); [updated 2008 May 23; accessed]. https://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4372b1-01-FDA,pdf.
   Google Scholar
• Vachhani H, Ribeiro BS, Schey R. 2020. Rumination syndrome: recognition and treatment. Curr Treat Options Gastro. 18(1):60–68.
   Google Scholar
• Vandereycken W. 1984. Neuroleptics in the short-term treatment of anorexia nervosa. A double-blind placebo-controlled study with sulpiride. Br J Psychiatry. 144(3):288–292.
   PubMedGoogle Scholar
• Vandereycken W, Pierloot R. 1982. Pimozide combined with behavior therapy in the short-term treatment of anorexia nervosa. A double-blind placebo-controlled cross-over study. Acta Psychiatr Scand. 66(6):445–450.
   PubMed Web of Science ®Google Scholar
• Viana M, Terreno E, Goadsby PJ, Nappi RE. 2014. Topiramate for migraine prevention in fertile women: reproductive counseling is warranted. Cephalalgia. 34(13):1097–1099.
   PubMed Web of Science ®Google Scholar
• Walsh BT, Agras WS, Devlin MJ, Fairburn CG, Wilson GT, Kahn C, Chally MK. 2000. Fluoxetine for bulimia nervosa following poor response to psychotherapy. Am J Psychiatry. 157(8):1332–1334.
   PubMed Web of Science ®Google Scholar
• Walsh BT, Gladis M, Roose SP, Stewart JW, Stetner F, Glassman AH. 1988. Phenelzine vs placebo in 50 patients with bulimia. Arch Gen Psychiatry. 45(5):471–475.
   PubMed Web of Science ®Google Scholar
• Walsh BT, Hadigan CM, Devlin MJ, Gladis M, Roose SP. 1991. Long-term outcome of antidepressant treatment for bulimia nervosa. Am J Psychiatry. 148(9):1206–1212.
   PubMed Web of Science ®Google Scholar
• Walsh BT, Kaplan AS, Attia E, Olmsted M, Parides M, Carter JC, Pike KM, Devlin MJ, Woodside B, Roberto CA, et al. 2006. Fluoxetine after weight restoration in anorexia nervosa. JAMA. 295(22):2605–2612.
   PubMed Web of Science ®Google Scholar
• Walsh BT, Stewart JW, Roose SP, Gladis M, Glassman AH. 1984. Treatment of bulimia with phenelzine. A double-blind, placebo-controlled study. Arch Gen Psychiatry. 41(11):1105–1109.
   PubMed Web of Science ®Google Scholar
• Wilfley DE, Crow SJ, Hudson JI, Mitchell JE, Berkowitz RI, Blakesley V, Walsh BT. 2008. Efficacy of sibutramine for the treatment of binge eating disorder: a randomized multicenter placebo-controlled double-blind study. Am J Psychiatry. 165(1):51–58.
   PubMed Web of Science ®Google Scholar
• Xu Z, Li Q. 2020. TAAR agonists. Cell Mol Neurobiol. 40(2):257–272.
   PubMed Web of Science ®Google Scholar
• Yancy WS Jr., Westman EC, McDuffie JR, Grambow SC, Jeffreys AS, Bolton J, Chalecki A, Oddone EZ. 2010. A randomized trial of a low-carbohydrate diet vs orlistat plus a low-fat diet for weight loss. Arch Intern Med. 170(2):136–145.
   PubMedGoogle Scholar
• You XX, Olten B, Gandhi K, Desai S, Gerolemou A. 2021. Pica in a patient with decompensated schizophrenia. Cureus. 13(9):e17964.
   PubMed Web of Science ®Google Scholar